How to Cite
Abstract
ABSTRACT
Background: antibody-mediated renal allograft rejection is a complication after kidney transplantation, and it has poor prognosis for graft survival. Plasmapheresis has been used with controversial results; few trials indicate a trend towards superior graft survival in patients receiving this treatment; however, the evidence remains weak. Objetive: the aim of this study was to describe the experience in treating Antibody-mediated renal allograft rejection with plasmapheresis in kidney transplant recipients. Methods: retrospective and descriptive study of the patients that underwent three to nine session of plasmapheresis as a treatment of severe Antibody-mediated renal allograft rejection in Pablo Tobón Uribe Hospital. Results: between August 2005 and June 2015, 769 patients underwent kidney transplantation at our institution; 26 patients received plasmapheresis as part of the treatment for Antibody-mediated renal allograft rejection. All patients received induction therapy. Maintenance therapy used was tacrolimus, mycophenolic acid and steroids in 80,8% of the patients and cyclosporine, micophenolic acid and steroids in 19,2%. Antibody mediated rejection had an early onset in 61,5% of the cases. At six and 12 months after therapy, 44% and 53,8% patients respectively were back on dialysis. Complications were reported in 53,8% of the patients (hypocalcaemia, hypotension and anaphylaxis). Conclusion: in this cohort, 50% of patients who received Plasmapheresis as therapy for severe Antibody-mediated renal allograft rejection presented loss graft after one year of follow up. It is necessary adding to this therapy
new treatment alternatives, among them intravenous immunoglobulin, rituximab, eculizumab and bortezomib. MÉD.UIS. 2016;29(2):41-8.
Keywords: Plasmapheresis. Graft rejection. Graft Survival. Kidney transplantation.
References
Lehrich RW, Rocha PN, Reinsmoen N, Greenberg A, Butterly DW, Howell DN, et al. Intravenous immunoglobulin and plasmapheresis in acute humoral rejection: experience in renal allograft transplantation. Hum Immunol. 2005;66(4):350-8.
Roberts DM, Jiang SH, Chadban SJ. The treatment of acute antibody-mediated rejection in kidney transplant recipients-a systematic review. Transplantation. 2012;94(8):775-83
Lucas JG, Co JP, Nwaogwugwu UT, Dosani I, Sureshkumar KK. Antibody-mediated rejection in kidney transplantation: an update. Expert Opin Pharmacother. 2011;12(4):579-92.
Gupta G, Abu Jawdeh BG, Racusen LC, Bhasin B, Arend LJ, Trollinger B, et al. Late antibody-mediated rejection in renal allografts: outcome after conventional and novel therapies. Transplantation. 2014;97(12):1240-6.
Tzvetanov I, Spaggiari M, Joseph J, Jeon H, Thielke J, Oberholzer J, et al. The use of bortezomib as a rescue treatment for acute antibody-mediated rejection: Report of three cases and review of literature. Transplant Proc. 2012;44(10):2971-5.
Mosquera Reboredo JM, Vázquez Martul E. Diagnostic criteria of antibody-mediated rejection in kidney transplants. Nefrologia. 2011;31(4):382-91.
Pascual M, Saidman S, Tolkoff-Rubin N, Williams W, Mauiyyedi S, Duan JM, et al. Plasma exchange and tacrolimus-mycophenolate rescue for acute humoral rejection in kidney transplantation. Transplantation. 1998;66(11):1460-4.
Puttarajappa C, Shapiro R, Tan HP. Antibody-mediated rejection in kidney transplantation: a review. J Transplant. 2012;2012:1-9.
Mosquera Reboredo JM, Vázquez Martul E. Criterios diagnósticos de rechazo mediado por anticuerpos en el trasplante renal. Nefrologia. 2011;31(4):382-91.
Seck SM, Bertrand D, Boucar D. Current indication of plasma exchanges in nephrology: a systematic review. Saudi J Kidney Dis Transpl. 2011;22(2):219-24.
Gungor O, Sen S, Kircelli F, Yilmaz M, Sarsik B, Ozkahya M, et al. Plasmapheresis therapy in renal transplant patients: five-year experience. Transplant Proc. 2011;43(3):853-7.
Brown CM, Abraham K a, O’Kelly P, Conlon PJ, Walshe JJ. Longterm experience of plasmapheresis in antibody-mediated rejection in renal transplantation. Transplant Proc. 2009;41(9):3690-2.
Pascual M, Saidman S, Tolkoff-Rubin N, Williams WW, Mauiyyedi S, Duan JM, et al. Plasma exchange and tacrolimusmycophenolate rescue for acute humoral rejection in kidney. Transplantation. 1998;66(11):1460-4.
Ibernón M, Gil-Vernet S, Carrera M, Serón D, Moreso F, Bestard O, et al. Therapy with plasmapheresis and intravenous immunoglobulin for acute humoral rejection in kidney transplantation. Transplant Proc. 2005;37(9):3743–5.
Fehr T, Gaspert A. Antibody-mediated kidney allograft rejection: therapeutic options and their experimental rationale. Transpl Int. 2012;25(6):623-32.
Kidney Disease: Improving Global Outcomes (KDIGO) transplant work group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant. 2009;9 Suppl 3:1-155.
Seck SM, Bertrand D, Boucar D. Current indication of plasma exchanges in nephrology: a systematic review. Saudi J Kidney Dis Transpl. 2011;22(2):219-24.
Lefaucheur C, Nochy D, Andrade J, Verine J, Gautreau C, Charron D, et al. Comparison of combination Plasmapheresis/IVIg/ anti-CD20 versus high-dose IVIg in the treatment of antibodymediated rejection. Am J Transplant. 2009;9(5):1099-107.
Böhmig GA, Wahrmann M, Regele H, Exner M, Robl B, Derfler K, et al. Immunoadsorption in severe C4d-positive acute kidney allograft rejection: a randomized controlled trial. Am J Transplant. 2007;7(1):117-21.
Sanchez AP, Ward DM. Therapeutic apheresis for renal disorders. Semin Dial. 2012;25(2):119-31.
Mengel M, Sis B, Haas M, Colvin RB, Halloran PF, Racusen LC, et al. Banff 2011 Meeting report: new concepts in antibodymediated rejection. Am J Transplant. 2012;12(3):563-70.
Solez K, Colvin R, Racusen L, Haas M, Sis B, Mengel M, et al. Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant. 2008;8(4):753-60.
El-Zoghby ZM, Stegall MD, Lager DJ, Kremers WK, Amer H, Gloor JM, et al. Identifying specific causes of kidney allograft loss. Am J Transplant. 2009;9(3):52-35.
Venetz J-P, Pascual M. New treatments for acute humoral rejection of kidney allografts. Expert Opin Investig Drugs. 2007;16(5):625-33.
Bartel G, Schwaiger E, Böhmig G. Prevention and treatment of alloantibody-mediated kidney transplant rejection. Transpl Int. 2011;24(12):1142–55.
Pape L, Becker JU, Immenschuh S, Ahlenstiel T. Acute and chronic antibody-mediated rejection in pediatric kidney transplantation. Pediatr Nephrol. 2015;417–24.
Orandi BJ, Zachary AA, Dagher NN, Bagnasco SM, GaronzikWang, Van Arendonk K J, et al. Eculizumab and Splenectomy as Salvage Therapy for Severe Antibody-Mediated Rejection After HLA Incompatible Kidney Transplantation. Transplantation. 2014;98(8):857–63.
Sin Y-H, Kim Y-J, Oh JS, Lee JH, Kim SM, Kim JK. Treatment of acute antibody-mediated rejection using bortezomib: a case report. Nephrology. 2015;20 Suppl 2:86–9.
Everly M, Everly J, Susskind B, Brailey P, Arend L, Alloway R, et al. Bortezomib provides effective therapy for antibody- and cellmediated acute rejection. Transplantation. 2008;86(12):1754-61.
Takeda A, Otsuka Y, Horike K, Inaguma D, Hiramitsu T, Yamamoto T, et al. Significance of C4d deposition in antibody-mediated rejection. Clin Transplant. 2012;26 Suppl 24:43–8.
Haas M, Sis B, Racusen LC, Solez K, Glotz D, Colvin RB, et al. Banff 2013 meeting report: Inclusion of C4d-negative antibodymediated rejection and antibody-associated arterial lesions. Am J Transplant. 2014;14(2):272–83.